IntegraGen Valuation

Is 7N8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7N8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7N8's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7N8's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7N8?

Key metric: As 7N8 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 7N8. This is calculated by dividing 7N8's market cap by their current revenue.
What is 7N8's PS Ratio?
PS Ratio	0.2x
Sales	€12.60m
Market Cap	€3.11m

7N8 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 7N8's PS Ratio compare to its peers?

The above table shows the PS ratio for 7N8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.1x
CNW co.don	0.7x	n/a	€6.5m
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
SBH Sangui Biotech International	3.8x	n/a	€419.8k
MDG1 Medigene	3.3x	16.1%	€24.9m
7N8 IntegraGen	0.2x	n/a	€3.1m

Price-To-Sales vs Peers: 7N8 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does 7N8's PS Ratio compare vs other companies in the DE Biotechs Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	7.9x	21.6%
7N8 IntegraGen	0.2x	n/a	US$3.27m
BIO3 Biotest	1.3x	-4.1%	US$1.42b
CNW co.don	0.7x	n/a	US$6.97m

8 Companies		Estimated Growth	Market Cap
Industry Avg.	7.9x	39.7%
7N8 IntegraGen	0.2x	n/a	US$3.27m

No more companies

Price-To-Sales vs Industry: 7N8 is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 7N8's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7N8 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 7N8's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.46

-3.4%

2.1%

Pharming Group

€498.9m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

-1.0%

-32.7%

Merck

US$249.2b

Operates as a healthcare company worldwide.

6MK

US$93.10

-1.0%

-0.1%